Pre-Conference Workshop

Pre-Conference Workshop

COMMON FEATURES OF NEURODEGENERATIVE DISEASES:
EXPLORING THE BRAIN-EYE CONNECTION AND BEYOND

Pre-Conference Full Day Satellite Workshop
Tuesday, March 26, 2019
08:30 -17:00

Pre-Registration is required. To register, please click here

Interdisciplinary research to compare and contrast human diseases is a key component of many academic and industry research programs. This workshop is intended to provide the participants with an understanding of the common and distinct features of neurodegenerative diseases, which include not only those affecting the brain, such as Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, vascular dementia, frontotemporal dementia, and mixed dementia; but also the ocular diseases including age-related macular degeneration, glaucoma, diabetic retinopathy, and inherited retinal degenerative diseases. This working group welcomes discussion input from participants and seeks to identify knowledge and barriers to bridging ocular neuroscience with the broader field of neurodegenerative diseases, which can collectively  guide interdisciplinary, collaborative, and innovative research.

 Co-Chair: Guojun Bu (USA)

 
 Co-Chair: Adriana Di Polo (Canada)
​Co-Chair: Todd Golde (USA) 

 
INTRODUCTORY REMARKS 
08:30WELCOME AND INTRODUCTIONS
Diane Bovenkamp (USA)
 
08:40

DEFINITIONS AND GENERAL DISCUSSION PRIMER
Guojun Bu (USA)

Adriana Di Polo (Canada)

Todd Golde (USA)

 
 DEFINITIONS AND GENERAL DISCUSSION PRIMER. SESSION I – WHY HAVE NEUROPROTECTIVE STRATEGIES FAILED AND HOW CAN WE MAKE IMPROVEMENTS? 
 SESSION I DISCUSSION PRIMER
Chair: Todd Golde (USA)
 
 Chair: Adriana Di Polo (Canada)  
09:05COMPLEXITIES IN GENETICS AND SYSTEMS BIOLOGY OF ALZHEIMER'S DISEASE AND RELATED DEMENTIAS
Nilufer Ertekin-Taner (USA)
 

09:25

DEVELOPMENT OF IMAGING TECHNOLOGIES FOR EYE AND BRAIN DISEASES
Francesca Cordeiro (UK)

 
09:45NERVE GROWTH FACTOR GENE THERAPY CLINICAL TRIAL FOR ALZHEIMER'S DISEASE: IN PROGRESS
 Mark Tuzsynski, USA
 
10:05

CLINICAL DEVELOPMENT OF A GENE THERAPY FOR AN INHERITED RETINAL DEGENERATIVE DISEASE: A SUCCESS STORY
 Daniel Chung, USA

 
10:25RE-PURPOSING DIABETES DRUGS FOR ALZHEIMER'S DISEASE: RATIONALE AND EXPERIENCE
Steven Arnold (USA)
 
10:45SECTION I GENERAL DISCUSSION / Q and A 
11:05COFFEE BREAK 
 

SESSION II - CAN WE MAKE MODELS THAT BETTER RECAPITULATE THE REAL-WORLD DISEASE SITUATION AND, IF SO, HOW WOULD WE KNOW THAT WE'VE SUCCEEDED?

 

 

 
11:25SESSION II DISCUSSION PRIMER 
 

 

Chair: Todd Golde (USA)

 
 Chair: Guojun Bu (USA)  
11:30CHIMERIC ALZHEIMER'S DISEASE MODEL: STEM-CELL-DERIVED HUMAN NEURONS TRANSPLANTED INTO MOUSE BRAIN
Bart De Strooper (United Kingdom)
 
11:50MODELING NEURODEGENERATIVE DISEASES WITH HUMAN NEURONS GENERATED BY DIRECT NEURONAL REPROGRAMMING
Andrew Yoo (USA)
 
12:10ADVANCES IN THE USE OF HUMAN PLURIPOTENT STEM CELLS, ORGANOIDS, AND TRANSPLANTABLE PHOTORECEPTORS AS MODELS FOR RETINAL DEGENERATION
 Rachael Pearson (UK)
 
12:30TOWARDS A MORE COMPLETE REPRESENTATION OF HUMAN DISEASE: ALZHEIMER'S MOUSE MODEL TAKES INTO ACCOUNT BETA-AMYLOID, TAU, AND SEEDING
Virginia Lee (USA)
 
12:50RETINA-IN-A-DISH: COMPLEX HUMAN IPSC-DERIVED 3D RETINAL ORGANOIDS
M. Valeria Canto-Soler (USA)
 
13:10SECTION II DISCUSSION / Q and A 
13:30LUNCH BREAK 
 SESSION III - HOW DO WE IMPROVE OUR UNDERSTANDING OF THE IMPACT OF CO-MORBIDITIES AND SYNERGISTIC PROCESSES, AND HOW DO WE EFFECTIVELY STUDY THEM? 
14:45SESSION III DISCUSSION PRIMER 
 Chair: Adriana Di Polo (Canada)  
 

Chair: Guojun Bu (USA)

 

 
14:50
GENETICS AND GENOMICS APPROACHES TO STUDY RESILIENCE TO COGNITIVE AGING AND ALZHEIMER’S DISEASE 
Cathrine Kaczorowski (USA)
 
15:10MULTIMODAL PREVENTIVE TRIALS FOR ALZHEIMER'S DISEASE: WHAT CAN WE LEARN FROM THE FINGER STUDY
 Miia Kivipelto, Sweden
 
15:30CONTRIBUTIONS TO ALZHEIMER'S DISEASE AND RELATED DEMENTIAS, STROKE, AND CEREBRAL HEMORRHAGES
Brian Bacskai, USA
 
15:50SLEEP AND ALZHEIMER'S DISEASE: A BI-DIRECTIONAL RELATIONSHIP
David Holtzman (USA)
 
16:10DEMENTIA IN THE OLDEST OLD
Claudia Kawas (USA)
 
16:30SECTION III DISCUSSION / Q and A 
16:50CLOSING REMARKS/DISCUSSION